Physician profile
Mohamed Eldaly
NPI 1962501718
$1,452.90
in general payments reported to CMS, 2019-2025
31 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $32.67 · 2021: $86.89 · 2022: $245 · 2023: $375 · 2024: $134 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.67 |
| Education | $120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $134.77 | 2019-2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $126.93 | 2022-2025 | |
| Pfizer INC. | $118.23 | 2019-2024 | |
| Amgen INC. | $109.68 | 2019-2023 | Kyprolis |
| Aveo Pharmaceuticals, INC. | $89.99 | 2025 | |
| Genzyme Corporation | $79.22 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $78.68 | 2019-2023 | Opdivo |
| Astellas Pharma US INC | $65.50 | 2019-2025 | Vyloy |
| Acrotech Biopharma INC. | $63.77 | 2021-2022 | |
| Daiichi Sankyo INC. | $55.03 | 2020-2025 | Enhertu, Datroway |
| Celgene Corporation | $48.22 | 2024-2025 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $46.74 | 2020-2024 | Rybrevant |
| Eisai INC. | $41.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.32 | 2023-2025 | Calquence, Enhertu |
| Sobi, INC | $34.89 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $29.64 | 2025 | |
| Organon LLC | $27.84 | 2022 | |
| Genentech USA, INC. | $25.60 | 2023 | Tecentriq |
| Kite Pharma, INC. | $25.06 | 2019 | |
| Tesaro, INC. | $24.50 | 2019 | |
| Myriad Genetic Laboratories, INC. | $21.97 | 2022 | |
| Abbvie INC. | $21.15 | 2022 | |
| Exelixis INC. | $20.62 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.88 | 2025 | Qinlock, Romvimza |
| Beigene USA, INC. | $18.47 | 2025 | Brukinsa |
| Napo Pharmaceuticals INC | $18.30 | 2024 | Gelclair Concentrated Oral Gel |
| Stemline Therapeutics INC. | $16.75 | 2019 | |
| Mirati Therapeutics, INC. | $16.05 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $13.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.96 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Eldaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.